CpG oligodeoxynucleotide-based therapy of lymphoid malignancies☆
Introduction
Over a hundred years have passed since the first anti-tumor effects of bacteria were identified by New York surgeon Dr. William Coley [1]. We now know that receptors in vertebral immune systems can recognize prokaryotic products that contain molecular patterns, and that such pattern receptors represent an important component of the innate immune response to prokaryotic infection. The prokaryotic bacterial DNA itself is one such molecular pattern, and has immunostimulatory properties due to sequence characteristics that are distinct from those found in eukaryotic DNA [2]. Multiple studies have demonstrated that bacterial DNA, and synthetic oligodeoxynucleotides that contain unmethylated CG dinucleotides and a phosphorothioate or chimeric backbone that renders them nuclease resistant (CpG ODN), have potent immunostimulatory effects. The pattern recognition receptor Toll-Like Receptor 9 (TLR 9) has been found to be the primary receptor for CpG ODN. The complex immunologic responses to CpG ODN by various immune cell subsets involve both direct effects mediated by TLR9 and indirect effects, resulting in the activation of NK cells, T cells, B cells, monocytes, macrophages and dendritic cells. The immunostimulatory effects of CpG ODN, and the therapeutic potential of this class of agents in cancer and other diseases, has been under investigation for the past decade, and are reviewed in detail elsewhere in this volume. B-cell malignancies are unique in that the target cells express TLR9. Lymphomas also tend to be more sensitive to cytokines and immune-based therapies than other malignancies [3]. Here, we provide a review of what is known about CpG ODN as a therapeutic agent for the treatment of lymphoid malignancies with a focus on B cell malignancies.
Section snippets
CpG ODN induced proliferation of malignant B cells
The description of the immunostimulatory effects of bacterial DNA and CpG ODN that reinvigorated our interest in the immunostimulatory effects of ODN described its anti-apoptotic effects on benign B cells [2]. It would seem counter intuitive to hypothesize that a class of agents that prevents apoptosis of B cells would be useful to treat malignant B cells. However, activation induced cell death has been well described as a mechanism that limits immune overstimulation. Thus, agents that
CpG ODN and activation induced cell death
As mentioned above, in the B cell malignancies, short term proliferation can lead to activation induced cell death. We found CpG ODN decreased numbers of viable CLL cells and increased numbers of apoptotic cells after 4 days when compared to control ODN or no ODN in 13 out of 20 primary CLL samples [11]. Cytogenetics impacted on response. Those subjects with good prognosis CLL cytogenetics were more likely to undergo apoptosis in response to CpG ODN than were subjects with poor prognosis
CpG ODN induced changes in immunophenotype of B cell malignancies
CpG ODN has other effects on malignant B cells that could impact on therapeutic response. CpG ODN 2006 can increase the expression of costimulatory molecules (CD40, CD80, CD86, CD54) on a variety of primary human malignant B cells [22]. CpG ODN also enhances expression of class I and class II MHC in most samples. In mixed lymphocyte reactions, CpG ODN markedly increased the T cell response to malignant B cells.
CpG ODN can also impact on expression of receptors for cytokines. Decker et al. found
CpG ODN and anti-CD20-based therapy
Anti-CD20 monoclonal antibody therapy has changed the way we treat B cell malignancies [25]. Rituximab, a chimeric anti-CD20 monoclonal antibody, is now a mainstay of treatment for the B cell malignancies. We and others have found that in vitro CpG ODN treatment of a variety of B cell malignancies increases expression of CD20 by the malignant cells [5], [22]. These studies demonstrated an inverse correlation between baseline expression of CD20 and its expression after exposure to CpG ODN, thus
Enhancing the immune response
Use of CpG ODN as immune adjuvants is outlined elsewhere in this volume and will not be reviewed in detail here. However, it is worth mentioning that cancer vaccine approaches have been studied in lymphoid malignancies, and CpG ODN has been shown to be a potent adjuvant in preclinical models of lymphoma [30], [31].
Given that CpG ODN enhances the immune response, and lymphomas tend to be sensitive to cytotoxic therapy, the combination of CpG ODN and cytotoxic therapy holds promise. This is based
CpG ODN-induced cytokines and lymphoid malignancy
Interferon alpha has been studied extensively as a treatment for both B and T cell lymphoma. When administered in purified or recombinant form, interferon alpha has clear anti-lymphoma activity in both B cell and T cell lymphoid malignancies when used alone and in combination with other agents [32], [33]. CpG ODN induce production by pDCs of a wide variety of cytokines including interferon alpha. Thus, secondary production of cytokines, including but not limited to interferon alpha, could
Class of CpG ODN and route of administration
Data to date raise interesting and unanswered questions concerning which class of CpG ODN, and which route of administration, is likely to be most effective as a treatment for lymphoid malignancies. As outlined elsewhere in this volume, there are different classes of CpG ODN. A-class CpG ODN are potent inducers of IFN alpha production, while B-class CpG ODN are strong stimulators of B cell responses. C-class CpG ODN have effects similar to the A and B classes. They activate B cells and induce
Summary
CpG ODN can mediate anti-tumor effects on lymphoid malignancies due to direct effects on cell viability, indirect effects due to CpG ODN-induced cytokines, and immunologic effects that result from enhanced development of an immune response (Fig. 1). Many lymphoid malignancies express TLR9 and, after a brief period of proliferation, have a tendency to undergo activation induced cell death in response to CpG ODN. Lymphoid malignancies are also sensitive to cytokines produced in response to CpG
References (39)
- et al.
Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses
Blood
(1987) - et al.
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
Blood
(2000) - et al.
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression
Blood
(2006) - et al.
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells. Costimulation with IL-2 results in a highly immunogenic phenotype
Exp. Hematol.
(2000) - et al.
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after Interleukin-21-based activation
Blood
(2006) - et al.
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity
Blood
(2005) - et al.
Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor
Blood
(1998) Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor
Semin. Oncol.
(2002)- et al.
A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles
J. Pharm. Sci.
(2007) The treatment of malignant tumors by repeated inoculations of Erysipelas with a report of ten original cases
Am. J. Med. Sci.
(1893)
CpG motifs in bacterial DNA trigger direct B-cell activation
Nature
Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma
Curr. Opin. Hematol.
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
J. Leukoc. Biol.
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides
Clin. Cancer Res.
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease
Leukemia
Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference
Leukemia
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells
J. Leukoc. Biol.
Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity
Leukemia
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
Neuro-Oncology
Cited by (33)
A comparison of cancer vaccine adjuvants in clinical trials
2023, Cancer Treatment and Research CommunicationsEnhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles
2022, Blood AdvancesCitation Excerpt :The increase in MDSCs from PTT can be mitigated with the incorporation of CpG deoxynucleotides.15 CpG deoxynucleotides are especially attractive in lymphoma because they stimulate immune responses and have direct cytotoxic effects against malignant B cells.16,17,18,19 Furthermore, PTT has also been evaluated in combination with checkpoint inhibitors with success in solid tumor murine models,20,21,22 but little is known about the immune effects of PTT in lymphoma.
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
2016, European Journal of CancerChimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice
2016, Cancer LettersCitation Excerpt :The TLR9 agonist CpG directly induces T-helper 1 biased immune responses in mice [27]. Some pre-clinical studies demonstrated that CpG improves the anti-tumor activity of immunotherapeutic reagents [28–30]. Our studies showed that a CTL epitope of HPV16 E7 protein formulated with PELC and CpG additively enhanced CTL responses and anti-tumor effects [16].
CpG oligodeoxynucleotide-loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells
2016, Biomedicine and PharmacotherapyCitation Excerpt :CpG-oligodeoxynucleotides (CpG-ODNs) can stimulate the immune system via interaction with Toll-like receptor 9 (TLR9) [1,2].
A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8<sup>+</sup> T-cell-mediated anti-tumor immunity
2014, Journal of Controlled ReleaseCitation Excerpt :The synthetic oligodeoxynucleotide (ODN) contains unmethylated cytosine–guanosine motifs (CpG) that are usually composed of a phosphorothioate nucleotide. The preclinical studies indicated that CpG has a good safety profile and improves the activity of vaccines targeting infectious diseases and cancer [58–64]. The Pan-DR Th epitope has been conjugated to a peptide of HPV16 E7 and formulated in a liposome and ISA-51 (called VacciMax®) with CpG and was shown to eradicate established tumors in vivo [65].
- ☆
This review is part of the Advanced Drug Delivery Reviews theme issue on “CpG Oligonucleotides as Immunotherapeutic Adjuvants: Innovative Applications and Delivery Strategies”.